Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Breast Neoplasms 5Polycystic Ovary Syndrome 3Neoplasm Metastasis 2Leiomyoma 2Vaginitis 1Triple Negative Breast Neoplasms 1Prostatic Neoplasms 1Pregnancy Complications 1Menorrhagia 1Estrogen Receptor Positive Breast Cancer 1Endometriosis 1Atrophic Vaginitis 1Anatomic Stage III Breast Cancer AJCC v8 1

Interventions

pembrolizumab 96Carboplatin 67Paclitaxel 56Cyclophosphamide 40Capecitabine 30Specimen Handling 28sacituzumab govitecan 25130-nm albumin-bound paclitaxel 24Gemcitabine 22Magnetic Resonance Spectroscopy 21Doxorubicin 20olaparib 19Taxes 19Biopsy 19Albumin-Bound Paclitaxel 19Drug Therapy 16atezolizumab 13Nivolumab 13toripalimab 12Radiotherapy 12Epirubicin 12durvalumab 11Docetaxel 10Cisplatin 10Bevacizumab 10eribulin 9fludarabine 8Standard of Care 7Radiation 7Injections 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Triple Negative Breast Neoplasms × Estradiol × 1 year × Clear all
NCT03941730 2026-05-12

Estradiol in Treating Patients With ER Beta Positive, Triple Negative Locally Advanced or Metastatic Breast Cancer

Mayo Clinic

Phase 2 Active not recruiting
8 enrolled 9 charts
Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡